Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 15;17:189. doi: 10.1186/s12974-020-01847-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 1 — Changes in CD4+ regulatory T cells (Treg), “effector” T cells (Teff), and Treg function in PBMC. a FACS gating strategy used to identify CD4 + CD25^hiCD127^lo/neg foxP3+ Tregs and CD4 + CD25 + CD127 + foxP3- Teff in PBMC (first four FACS plots, left to right) and in PBMC depleted of CD25+ Tregs (fifth FACS plot, right). b-e Illustrate changes over time at each study timepoint for each individual patient (open symbols), compared with baseline (M0) values. b Changes in Tregs. c Changes in Teff. d Changes in Teff:Treg ratio. e Changes in Treg function, indicated as percent rebound in CD25-depleted PBMC compared to undepleted PBMC. Data in all panels represent median/IQR values for all patients at each timepoint. p values indicate significant changes from baseline (M0) as follows: ****p ≤ 0.0001, ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05; mixed effects ANOVA with Tukey’s corrections for multiple comparisons